Novo Nordisk A/S

Novo Nordisk A/S researches, develops, manufactures, and distributes pharmaceutical products. The company operates through two primary segments: Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes Care segment focuses on products for diabetes, obesity, cardiovascular conditions, and other emerging therapy areas. The Rare Disease segment provides products for rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Novo Nordisk A/S also offers medical devices such as NovoPen 6 and NovoPen Echo Plus, which are smart insulin pens, and Dose Check, an insulin dose guidance application. Additionally, it provides growth hormone pens and injection needles. The company's product portfolio includes Wegovy pill, an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. Novo Nordisk A/S has a global presence, operating in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.